EDAP's Ablatherm® Robotic HIFU Treatments Performed at University of Minnesota

LYON, France, February 27, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at the University of Minnesota, Minneapolis, using the Company's FDA-cleared Ablatherm Robotic HIFU.  The Department of Urology at the University of Minnesota Medical School is recognized as one of the leading urology departments in the United States.

Dr. Badrinath Konety, Chair, Department of Urology University of Minnesota Director, Institute for Prostate and Urologic Cancers, commented: "We are delighted to be the first center in the upper Midwest to offer Ablatherm Robotic HIFU. We find it to be an excellent low morbidity treatment option for appropriately selected patients with prostate cancer."

Marc Oczachowski, EDAP TMS Chief Executive Officer, added: "We are very pleased to add the prestigious University of Minnesota to our list of HIFU centers in the U.S. and to work in close collaboration with Dr. B. Konety in supporting HIFU adoption among the urology community. By partnering with HIFU Solution, we increase the availability of HIFU treatments for U.S. patients by offering mobile HIFU access to hospitals and clinics. We look forward to continuing to extend our HIFU education programs throughout the country to as many American urologists as possible."

Dr. P. Narayan MD, HIFU Solution Medical Director, commented: "It is with great pleasure that HIFU Solution, in conjunction with Urologists and Surgical centers, was able to offer mobile HIFU to patients of the state of Minnesota, utilizing the innovative Ablatherm treatment device from EDAP. We will be offering this HIFU service to many doctors in the urology community around the country."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm is approved for commercial distribution in Europe and other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

About HIFU Solution

HIFU Solution combines compassionate, highly qualified and experienced physicians and professionals with pioneering, noninvasive HIFU technology for the diagnosis and treatment of prostate cancer to provide unparalleled patient care. The company aims to provide patients and their families with answers about the diagnosis and treatment options, and a clear path forward. HIFU Solution is comprised of a network of twenty-six qualified physicians placed in ten states. With five centers established on the East Coast, HIFU Solution plans to launch five more centers in the Midwest and Western parts of the country. For more information on the company, please visit http://www.hifusolution.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Investor Contact

CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital

Company Contact

Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

News Provided by Acquire Media